Comparing the effectiveness of IO-based combination regimens as first-line treatment for advanced clear-cell renal cell carcinoma (ccRCC). This is an ASCO Meeting Abstract from the 2025 ASCO ...

This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text component.

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Proton pump inhibitors and antibiotics increase mortality risk, while statins, renin-angiotensin system inhibitors.

Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...

Belzutifan plus cabozantinib maintained durable antitumor activity in advanced clear cell renal cell carcinoma, per phase 3 LITESPARK-003 data.

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, ...

Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma. Clin Cancer Res. 2023; 29(7):1220-1230. Vano YA, Elaidi R, Bennamoun M, et al.

Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a form of renal cell carcinoma (RCC) driven by a mostly inherited mutation.

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...